Rifaximin 550 mg TID for IBS-D: 14 Days
The FDA-approved and guideline-recommended duration of rifaximin (Xifaxan) 550 mg three times daily for IBS-D is 14 days (2 weeks). 1, 2
Treatment Protocol
Initial Course
- Dose: Rifaximin 550 mg orally three times daily
- Duration: 14 days
- Administration: With or without food 2
Retreatment Strategy
If symptoms recur after initial response, patients can be retreated up to 2 additional times using the same 14-day regimen (550 mg TID for 14 days). 1
The retreatment protocol is based on high-quality evidence from the TARGET 3 trial 3, which demonstrated:
- Patients who responded to initial open-label rifaximin and then relapsed were randomized to receive up to 2 repeat 14-day courses
- The second repeat course was initiated 10 weeks after completion of the first repeat treatment
- Retreatment showed significant efficacy (38.1% responders vs 31.5% placebo, P=0.03) 3
Clinical Response Timeline
Assess response during the 4 weeks AFTER completing the 14-day treatment course, not during treatment itself. 1 The FDA responder endpoint requires:
- ≥30% reduction in abdominal pain score, AND
- ≥50% reduction in days with loose stools (Bristol Stool Scale type 6 or 7)
- For at least 2 of the 4 weeks post-treatment
Important Caveats
Do NOT use continuous or prolonged courses beyond 14 days. The evidence base and FDA approval are specifically for short 14-day courses, not extended therapy. 1, 2
Maximum lifetime exposure: Up to 3 total courses (initial + 2 retreatments) based on FDA labeling and clinical trial data. 1
Relapse definition for retreatment consideration: Loss of treatment response for either abdominal pain (failure to maintain 30% improvement) or stool consistency (failure to maintain 50% improvement) for 3 of 4 consecutive weeks. 1
The British Society of Gastroenterology guidelines 4 acknowledge rifaximin's efficacy but note its effect on abdominal pain is limited compared to stool consistency and bloating, which should inform patient selection and counseling.